Document Type
Article
Publication Date
2-2011
Abstract
Vaccines, analgesia, and antibiotics embody some of the most
enduring therapeutic breakthroughs that have transformed
medicine. Building on such fine paradigms of biomedical
innovation, the evolution of technologies has increasingly
sparked spectacular advances across the continuum of wellness
and disease-spanning medical and surgical specialties. Discovery
science—fueled by government and private sector resources—has
systematically instituted the principles of modern healthcare
delivery ensuring that medical practice is based on up-to-date
scientifi c evidence. Th e harmony between science, technology,
and resources has culminated in a golden age of discovery and
translation, eradicating infections, curing cancers, and palliating
endocrine and metabolic diseases. Indeed, proven therapeutic and
preventive approaches have progressively moved into everyday
practice.
Recommended Citation
Waldman, Scott A. and Terzic, Andre, "Clinical Translational Science 2020: Disruptive Innovation Redefines the Discovery-Application Enterprise" (2011). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 9.
https://jdc.jefferson.edu/petfp/9
Comments
This article has been peer reviewed. It is the authors' final version prior to publication in Clinical and Translational Science Volume 4, Issue 1, February 2011, Pages 69-71. The published version is available at DOI: 10.1111/j.1752-8062.2011.00261.x. Copyright © John Wiley Sons, Inc.